small molecule

NAYZILAM

MIDAZOLAM

Loss of exclusivityJanuary 2028latest FDA-listed patent expiry

CompanyUCB →View the full company profile on CliffBio

Drug detail

Brand name	NAYZILAM
Active ingredient	MIDAZOLAM
Strength	5MG/SPRAY
Dosage form	SPRAY
Route	NASAL
Modality	Small molecule
FDA approval	May 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
9687495	January 2028	product
9289432	January 2028	product
8217033	January 2028	product
8809322	January 2028	product

Regulatory exclusivity

Code	Expires
ODE-243	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from UCB